Evidence map›Paper›PMID 31205501›Full record

ArticleTherapeutic advances in medical oncology2019

Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study.

Florian Struller, Philipp Horvath, Wiebke Solass, Frank-Jürgen Weinreich, Dirk Strumberg, Marios K Kokkalis, Imma Fischer, Christoph Meisner, Alfred Königsrainer, Marc A Reymond

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01854255 (Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy), which is not on this map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01854255 phase2completednot on this map

Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Patients With Gastric Cancer and Peritoneal Carcinomatosis: an Open-label, Single-arm, Phase II Clinical Trial

TypeinterventionalSponsorRuhr University of BochumRan2013 to 2016Enrolled35ConditionsGastric CancerArmsdoxorubicin and cisplatin
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Catheter based intraperitoneal chemotherapy using taxane for peritoneal metastases from gastric cancer: from bench to bedside-a narrative review.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Florian StrullerDepartment of General and Transplant Surgery, Tübingen, University Hospital, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany.
Philipp HorvathDepartment of General and Transplant Surgery, University Hospital Tübingen, Germany.
Wiebke SolassDepartment of Pathology, University Hospital Tübingen, Germany.
Frank-Jürgen WeinreichDepartment of General and Transplant Surgery, University Hospital Tübingen, Germany.
Dirk StrumbergDepartment of Medical Oncology, Marien Hospital, Ruhr University Bochum, Germany.
Marios K KokkalisDepartment of General and Transplant Surgery, University Hospital Tübingen, Germany.
Imma FischerInstitute for Clinical Epidemiology and Applied Biometrics, University Hospital Tübingen, Germany.
Christoph MeisnerInstitute for Clinical Epidemiology and Applied Biometrics, University Hospital Tübingen, Germany.
Alfred KönigsrainerDepartment of General and Transplant Surgery, University Hospital Tübingen, Germany.
Marc A ReymondDepartment of General and Transplant Surgery, University Hospital Tübingen, Germany National Center for Pleura and Peritoneum, University Hospital, Tübingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEfficacy of second-line systemic chemotherapy in recurrent gastric cancer with peritoneal metastasis (RGCPM) is limited. We assessed the feasibility, safety and possible efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with RGCPM after ⩾1 line of palliative intravenous chemotherapy.

methodsIn this open-label, single-arm, monocentric phase II ICH-GCP clinical trial, patients were scheduled for three courses of PIPAC with cisplatin 7.5 mg/m

resultsA total of 25 patients were enrolled and available for the analysis of the primary endpoint. Of those 25 patients, 10 (40%) had a radiological complete, partial response or stable disease. Median OS [intention to treat (ITT)] was 6.7 months, median TTP was 2.7 months. Complete or major regression on histology were observed in 9/25 patients (36%, ITT) or 6/6 [100%, per protocol (PP)] patients. There were no suspected unexpected serious adverse reactions, no treatment-related deaths, no CTCAE grade 4 toxicity and three (12%) grade 3 toxicities. Changes in the QLQ-C30 scores during PIPAC C/D therapy were small and not significant.

conclusionsPIPAC C/D was well tolerated and active in patients with RGCPM. Survival was encouraging. Randomized controlled trials should now be designed in this indication.

Indexed as

Cisplatindoxorubicingastric cancerhistological regressionintraperitoneal chemotherapyobjective tumor responseperitoneal metastasispressurized intraperitoneal aerosol chemotherapy (PIPAC)

Identifiers

PMID31205501
PMCPMC6535725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.